Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was $7.55 for the day, down -5.03% from the previous closing price of $7.95. In other words, the price has decreased by -$5.03 from its previous closing price. On the day, 4.49 million shares were traded.
Ratios:
Our analysis of AUPH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.10 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.59. For the most recent quarter (mrq), Quick Ratio is recorded 5.11 and its Current Ratio is at 5.60. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.19.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 09 ’24 when TANG KEVIN bought 500,000 shares for $9.09 per share. The transaction valued at 4,545,000 led to the insider holds 8,429,500 shares of the business.
TANG KEVIN bought 400,000 shares of AUPH for $3,604,000 on Dec 06 ’24. The Director now owns 7,929,500 shares after completing the transaction at $9.01 per share. On Dec 05 ’24, another insider, TANG KEVIN, who serves as the Director of the company, bought 300,000 shares for $8.91 each. As a result, the insider paid 2,673,000 and bolstered with 7,529,500 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.91 while its Price-to-Book (P/B) ratio in mrq is 2.78.
Stock Price History:
Over the past 52 weeks, AUPH has reached a high of $10.67, while it has fallen to a 52-week low of $4.71. The 50-Day Moving Average of the stock is -8.85%, while the 200-Day Moving Average is calculated to be 7.26%.
Shares Statistics:
A total of 143.11M shares are outstanding, with a floating share count of 128.78M. Insiders hold about 10.06% of the company’s shares, while institutions hold 39.38% stake in the company.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Aurinia Pharmaceuticals Inc (AUPH) in the stock market.The consensus estimate for the next quarter is $0.12, with high estimates of $0.14 and low estimates of $0.1.
Analysts are recommending an EPS of between $0.58 and $0.45 for the fiscal current year, implying an average EPS of $0.49. EPS for the following year is $0.84, with 3.0 analysts recommending between $1.11 and $0.7.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $62.1M to a low estimate of $60.69M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $50.3MFor the next quarter, 4 analysts are estimating revenue of $64.04M. There is a high estimate of $65.5M for the next quarter, whereas the lowest estimate is $63.2M.
A total of 4 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $260M, while the lowest revenue estimate was $255.8M, resulting in an average revenue estimate of $257.95M. In the same quarter a year ago, actual revenue was $235.13MBased on 6 analysts’ estimates, the company’s revenue will be $319.69M in the next fiscal year. The high estimate is $394.71M and the low estimate is $290M.
